Hemab Therapeutics Holdings, Inc. COAG
43.72 USD +0.62 (+1.44%)
Nov 4, 2026, 11:48 AM EST
42.01 Day range 45.00
23.00 52-week range 55.42
- YTD
- +28.59%
- 1 year
- +28.59%
Analyst view
Price target (mean) 62.67 +43.3% upside
Now 43.72
- Target (low)
- 58.00
- Target (mean)
- 62.67
- Target (high)
- 70.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.51529 | -0.55 – -0.41 | 0.00 | 0.0% | 0 | 0.0% | 5 |
| Next quarter | -0.56978 | -0.62 – -0.50 | 0.00 | 0.0% | 0 | 0.0% | 5 |
| Current year | -3.11 | -3.23 – -2.77 | 0.00 | 0.0% | 0 | 0.0% | 5 |
| Next year | -2.55 | -2.81 – -2.30 | -3.11 | +18.1% | 0 | 0.0% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | JP Morgan | Initiated | — | Overweight |
| Oct 12, 2026 | Rodman & Renshaw | Initiated | — | Buy |
| Aug 12, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Aug 11, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 13, 2026 | Jefferies | Maintained | Buy | Buy |
| Jul 13, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jul 13, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 26, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 17, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| May 26, 2026 | Wedbush | Initiated | — | Outperform |
| May 26, 2026 | Jefferies | Initiated | — | Buy |
| May 26, 2026 | Evercore ISI Group | Initiated | — | Outperform |
| May 26, 2026 | Goldman Sachs | Initiated | — | Buy |